

ASX Release

Recce Continues Strategic Partnership with Murdoch Children's Research Institute

Sydney Australia, 27 February 2024: Recce Pharmaceuticals Limited (**ASX:RCE**, **FSE:R9Q**), (the **Company**), the Company developing a New Class of Synthetic Anti-Infectives, is pleased to announce the continuation of the work within the Company's Anti-Infective Research (AIR) Unit located within Murdoch Children's Research Institute (MCRI).

In 2023, Recce established a dedicated Anti-Infective Research Unit led by MCRI researcher Dr Sohinee Sarkar within MCRI's state-of-the-art research facilities, underscoring the commitment of both organisations to drive innovation in the field of anti-infective therapeutics. By leveraging MCRI's world-leading expertise and resources, the Company continues to streamline its ongoing pre-clinical programs while investigating new indications for future clinical trials.

Building on the success of the existing partnership, the collaboration between Recce and MCRI has been instrumental in providing significant results in ongoing pre-clinical programs. Notably, this partnership has played a pivotal role in the delivery of positive efficacy data from RECCE[®] 327's pre-clinical programs against a broad range of life-threatening infectious pathogens such as *Escherichia coli* (which can lead to UTI's/ Urosepsis), *Mycobacterium abscessus*, *Streptococcus pneumoniae* and *Neisseria gonorrhoeae* – a priority pathogen on the World Health Organisation's list of bacteria that poses greatest threat to human health.

Prof Andrew Steer, Theme Director Infection, Immunity and Global Health MCRI said, "The threat of antibiotic resistance is greater now than ever, and commercial-academic partnerships are crucial to advance antibiotic discovery. The partnership between Recce and MCRI will advance efforts and promote Australian leadership in the fight against antibiotic resistance."



ASX: RCE, FSE: R9Q

Head Office: Level 23, 180 George St, Salesforce Tower, SYDNEY NSW 2000 T +61 (02) 9256 2505

R&D Centre - Perth: Suite 10, 3 Brodie Hall Drive, Technology Park, BENTLEY WA 6102 T +61 (8) 9362 9860

Washington Office: 1717 Pennsylvania Avenue NW, Suite 1025, WASHINGTON DC 20006 USA

The collaboration between the Company's AIR Unit and MCRI exemplifies the power of partnership in driving medical breakthroughs. As both organisations work together to advance anti-infective research, they remain committed to improving patient outcomes and addressing global health challenges.

James Graham, Chief Executive Officer of Recce Pharmaceuticals said, "Our continued work at the AIR Unit aligns with Murdoch Children's mission to address the global health threat of anti-microbial resistance through innovative research. The synergy between our organisations will undoubtedly lead to ground-breaking discoveries that have the potential to transform the landscape of infectious disease treatment."

This announcement has been approved for release by Recce Pharmaceuticals Board.

About Murdoch Children's Research Institute

Murdoch Children's Research Institute is the largest child health research institute in Australia committed to making discoveries and developing treatments to improve child and adolescent health in Australia and around the world. They are pioneering new treatments, trialling better vaccines and improving ways of diagnosing and helping sick babies, children and adolescents. It is one of the only research institutes in Australia to offer genetic testing to find answers for families of children with previously undiagnosed conditions.

About Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd (ASX: **RCE**, FSE: **R9Q**) is developing a New Class of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens.

Recce's anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE[®] 327 as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria including their superbug forms; RECCE[®] 435 as an orally administered therapy for bacterial infections; and RECCE[®] 529 for viral infections. Through their multi-layered mechanisms of action, Recce's anti-infectives have the potential to overcome the hypercellular mutation of bacteria and viruses – the challenge of all existing antibiotics to date.

The FDA has awarded RECCE[®] 327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act – labelling it for Fast Track Designation, plus 10 years of market exclusivity post approval. Further to this designation, RECCE[®] 327 has been included on The Pew Charitable Trusts Global New Antibiotics in Development Pipeline as the world's only synthetic polymer and sepsis drug candidate in development. RECCE[®] 327 is not yet market approved for use in humans with further clinical testing required to fully evaluate safety and efficacy.

Recce wholly owns its automated manufacturing, which is supporting present clinical trials. Recce's anti-infective pipeline seeks to exploit the unique capabilities of its technologies targeting synergistic, unmet medical needs.



Chief Executive Officer
James Graham
Recce Pharmaceuticals Ltd
james.graham@recce.com.au

Media and Investor Relations

Australia
Andrew Geddes
CityPR
+61 408 677 734
ageddes@citypublicrelations.com.au

USA
Michael Fitzhugh
LifeSci Communications
mfitzhugh@lifescicomms.com

Europe
Guillaume van Renterghem
LifeSci Advisors
gvanrenterghem@lifesciadvisors.com